share_log

Truist Securities Maintains Buy on Sutro Biopharma, Raises Price Target to $25

Benzinga Real-time News ·  Jan 13, 2023 08:27

Truist Securities analyst Asthika Goonewardene maintains Sutro Biopharma (NASDAQ:STRO) with a Buy and raises the price target from $21 to $25.

Disclaimer: This content is for informational and educational purposes only and does not constitute a recommendation or endorsement of any specific investment or investment strategy. Read more
    Write a comment